PMID- 36045013
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230213
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 21
IP  - 1
DP  - 2023 Feb
TI  - Renal Sarcoma: A Population-Based Study.
PG  - 155-161
LID - S1558-7673(22)00167-7 [pii]
LID - 10.1016/j.clgc.2022.07.012 [doi]
AB  - INTRODUCTION: Renal sarcomas are exceedingly rare and lack a prognostic stage 
      classification. We thus aimed to investigate the contemporary clinicopathologic 
      characteristics and outcomes of renal sarcomas at a national level. PATIENTS AND 
      METHODS: We utilized the Surveillance, Epidemiology, and End Results database to 
      extract data on patients with renal sarcoma diagnosed between 2004 and 2015. We 
      estimated median, 1-, 3-, and 5-year overall survival (OS) probabilities via 
      Kaplan-Meier curves and used multivariable regression to compare OS between 
      different patient groups. RESULTS: We identified 365 patients; at diagnosis, 104 
      patients (28.5%) had stage I disease (T1N0M0), 133 patients (36.4%) patients had 
      stage II disease (T2-4N0M0), and 117 patients (32.1%) patients had stage III 
      disease (any T, N1, or M1). Median survival was 105 months (interquartile range 
      [IQR], 29 - not reached) for stage I disease, 46 months (IQR 14-118 months) for 
      stage II disease, 8 months (IQR 3-28 months) for stage III disease, and 32 months 
      (IQR, 8-116 months) for the entire cohort. Patient age (hazard ratio [HR] for 
      death [per year] 1.02, 95% confidence interval [95% CI] 1.00-1.04), stage (II vs. 
      I: HR 1.71, 95% CI 1.00-2.92; III vs. I: HR 4.93, 95% CI 2.68-9.05), grade (grade 
      3 vs. grade 1: 3.07, 95% CI 1.18-8.00; grade 4 vs. grade 1: HR 3.66, 95% CI 
      1.41-9.49), and possessing medical insurance (HR 0.40, 95% CI 0.16-0.94) were 
      independently and significantly associated with OS. Performance of nephrectomy 
      also trended towards independently improving OS (HR 0.23, 95% CI 0.05-1.09). 
      CONCLUSION: A novel staging classification for renal sarcomas into a 3-stage 
      system based on Tumor Node Metastasis (TNM) criteria produces distinct survival 
      curves, although further studies are needed to robustly assess its validity.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Alevizakos, Michail
AU  - Alevizakos M
AD  - Hematology/Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA. 
      Electronic address: mich.alevizakos@gmail.com.
FAU - Gaitanidis, Apostolos
AU  - Gaitanidis A
AD  - Department of Surgery, Eastern Virginia Medical School, Norfolk, VA.
FAU - Korentzelos, Dimitrios
AU  - Korentzelos D
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.
FAU - Basourakos, Spyridon P
AU  - Basourakos SP
AD  - Department of Urology, New York Presbyterian Hospital/Weill Cornell Medical 
      Center, New York, NY.
FAU - Burgess, Melissa
AU  - Burgess M
AD  - Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA.
LA  - eng
PT  - Journal Article
DEP - 20220730
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
SB  - IM
MH  - Humans
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - *Kidney Neoplasms/epidemiology/surgery
MH  - Prognosis
MH  - *Sarcoma/epidemiology/therapy
MH  - SEER Program
OTO - NOTNLM
OT  - Epidemiology
OT  - Renal
OT  - SEER
OT  - Sarcoma
OT  - Staging
EDAT- 2022/09/01 06:00
MHDA- 2023/02/01 06:00
CRDT- 2022/08/31 22:02
PHST- 2021/11/11 00:00 [received]
PHST- 2022/07/22 00:00 [revised]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/09/01 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
PHST- 2022/08/31 22:02 [entrez]
AID - S1558-7673(22)00167-7 [pii]
AID - 10.1016/j.clgc.2022.07.012 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2023 Feb;21(1):155-161. doi: 10.1016/j.clgc.2022.07.012. 
      Epub 2022 Jul 30.